Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Daily News

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Michael O'Riordan

September 16, 2016

News Daily News

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Michael O'Riordan

September 16, 2016

News Daily News

Demasiados Elementos en Juego: La Existencia de Diferentes y Discordantes Directrices Hace que la Valoración del Riesgo de ECV sea Confusa

Michael O'Riordan

September 16, 2016

News Daily News

Increased Consumption of Subsidized Foods Ups Cardiometabolic Risk

Leah Lawrence

July 06, 2016

News Industry News

Capricor Therapeutics Reports Positive 12-Month Data from the DYNAMIC Clinical Trial

June 17, 2016

News Daily News

Cardiology Groups Applaud FDA’s Draft Guidance Setting Voluntary Sodium Cuts for Processed Food Industry

Shelley Wood

June 01, 2016

News Daily News

NHANES: Just Over Half of Eligible Patients Taking Cholesterol-Lowering Medication

Michael O'Riordan

December 08, 2015

News Industry News

Symic Biomedical Selects Vascular Clinical Candidate

July 20, 2015

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol

August 28, 2014

News Industry News

CardioVascular BioTherapeutics Submits FDA Application for 'Fast Track' Status for CVBT-141B, CVBT's Biological Treatment for Diabetes Patients

February 02, 2011

Advertisement

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Demasiados Elementos en Juego: La Existencia de Diferentes y Discordantes Directrices Hace que la Valoración del Riesgo de ECV sea Confusa

Increased Consumption of Subsidized Foods Ups Cardiometabolic Risk

Capricor Therapeutics Reports Positive 12-Month Data from the DYNAMIC Clinical Trial

Cardiology Groups Applaud FDA’s Draft Guidance Setting Voluntary Sodium Cuts for Processed Food Industry

NHANES: Just Over Half of Eligible Patients Taking Cholesterol-Lowering Medication

Symic Biomedical Selects Vascular Clinical Candidate

Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol

CardioVascular BioTherapeutics Submits FDA Application for 'Fast Track' Status for CVBT-141B, CVBT's Biological Treatment for Diabetes Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content